{"preliminary_commentary":{"by_channel":{"x_thread":8},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04995523\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"ARTEMIDE-01","nct_id":"NCT04995523","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=artemide-01-nct04995523. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"ARTEMIDE-01","arms":[{"description":"Rilvegostomig Intravenous (IV) monotherapy","label":"Dose Escalation Part A: Checkpoint inhibitor (CPI) experienced Non-small Cell Lung Cancer (NSCLC)","type":"EXPERIMENTAL"},{"description":"Rilvegostomig IV monotherapy","label":"Dose Expansion Part B: CPI experienced NSCLC","type":"EXPERIMENTAL"},{"description":"Rilvegostomig IV monotherapy","label":"Dose Expansion Part C: CPI Naive NSCLC","type":"EXPERIMENTAL"},{"description":"Rilvegostomig IV monotherapy","label":"Dose Expansion Part D: CPI Naive NSCLC","type":"EXPERIMENTAL"},{"description":"Rilvegostomig IV monotherapy","label":"Dose Expansion Part E: treatment Naive Squamous NSCLC","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2028-06-01","type":"ESTIMATED"},"conditions":["Non-Small-Cell Lung Carcinoma"],"enrollment":{"count":212,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"AZD2936","otherNames":["Rilvegostomig"],"type":"DRUG"}],"last_update":"2026-07-14","lead_sponsor":"AstraZeneca","official_title":"Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2026-08-28","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Percentage of participants with adverse events (AEs) and immune mediated AEs (imAEs), serious AEs (SAEs), dose limiting toxicities (DLTs), vital signs, and abnormal laboratory parameters","timeFrame":"Part A, B, C, D and E: From the time of informed consent until 90 days after the last dose of rilvegostomig"},{"measure":"Rate of rilvegostomig discontinuation due to toxicity","timeFrame":"Part A, B, C, D and E: From first dose to the last dose of rilvegostomig (an average of 6 months)"},{"measure":"Objective Response Rate (ORR)","timeFrame":"Part B, C, D and E: From first dose of rilvegostomig to progressive disease (PD) or death in the absence of disease progression (approximately 2 years)"}],"references":[],"start_date":{"date":"2021-09-14","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC","url":"https://clinicaltrials.gov/study/NCT04995523"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/artemide-01-nct04995523"}